DocGo (DCGO) Stock Forecast & Price Target

DocGo is expected to experience a decline in revenue and adj-EBITDA due to a decrease in migrant-related revenue and aggressive cost-cutting targets. However, the company has shown solid growth in its core business lines, including healthcare in the home and transportation. The recent expansion of a national payer relationship in Kentucky and the steady trajectory of its subsidiary, SteadyMD, indicate positive prospects for the company. There is also some uncertainty regarding the potential decrease in testing revenue post-COVID, but our positive outlook is based on the company's strong performance and potential for growth in these profitable segments.

DocGo is facing multiple challenges that have resulted in a negative outlook on their stock, including slow growth in their core payer/provider mobile health businesses, difficulties ramping up their go-forward business, and ongoing costs from the migrant revenue. The company's profitability is also a concern, with adj-EBITDA missing expectations in 2025 and expected to continue into 2026. Despite ongoing efforts to reposition the business for growth, their revenue and organic growth is declining, and their recent strategic review is not expected to result in immediate improvement. Additionally, DCGO faces hesitancy from investors due to their SPAC merger and lingering doubts about the durability of their revenue stream, resulting in a discounted valuation. As a result, the company's stock outlook remains negative until there are clear signs of growth and profitability in their core businesses.